Drug Profile
OSE 2101
Alternative Names: EP-2101; IDM 2101; OSE-2101; TedopiLatest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator IDM Pharma
- Developer Bristol-Myers Squibb; GERCOR; OSE Immunotherapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Non-small cell lung cancer
- Phase II Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer
Most Recent Events
- 19 Jan 2024 Dossier receives positive review from the US FDA for OSE 2101 in Non-small cell lung cancer, before January 2024
- 19 Jan 2024 OSE Immunotherapeutics announces intention to submit an early access dossier in 2022
- 19 Jan 2024 OSE Immunotherapeutics plans a phase III trial for Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater) in US in Q2 of 2024 and extension to Europe in S2 2024 (IV)